Cornea/External Disease News

I recently performed epi-off cross-linking on a 23-year-old male patient whose keratoconus was still progressing despite two prior cross-linking procedures.

Integrated data from the phase 2 ONSET-1 and phase 3 ONSET-2 clinical trials showed that OC-01 nasal spray effectively improves endogenous basal tear production in a heterogeneous dry eye disease population.

ST-100, a novel dry eye treatment, achieved positive topline results in a phase 2 clinical trial, according to a press release from Stuart Therapeutics.

An FDA clearance and dry eye disease trials led cornea coverage from December.

The top Ocular Surgery News cover stories of 2021 include looks at noninvasive presbyopia treatment, corneal cross-linking innovation and more.

The top pieces of news in ophthalmology in December include acquisitions and FDA clearances.

The most-read FDA approval stories of 2021 include Tyrvaya nasal spray and Byooviz, the first ophthalmology biosimilar to receive FDA approval.

Reproxalap did not meet the primary endpoint of ocular redness but achieved statistical significance in the secondary endpoint of Schirmer test in a phase 3 clinical trial, according to a press release from Aldeyra Therapeutics.

The TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction, according to a press release from Sight Sciences.

Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and refractive surgery specialists, here to discuss some of the latest hot topics in ophthalmology.